Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating sitagliptin 100 mg in participants with Type 2 Diabetes Mellitus who have inadequate glycemic control; the trial is completed with resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Januvia (sitagliptin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2012-08-07